Float Short %

10.45

Margin Of Safety %

Put/Call OI Ratio

0.12

EPS Next Q Diff

-0.01

EPS Last/This Y

0.49

EPS This/Next Y

0.02

Price

1.45

Target Price

4.94

Analyst Recom

2.09

Performance Q

43.14

Upside

-1,275.3%

Beta

2.2

Ticker: FATE

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	FATE	1.21	0.16	0.03	7083
2026-01-26	FATE	1.235	0.16	0.02	7342
2026-01-27	FATE	1.305	0.14	0.00	8040
2026-01-28	FATE	1.22	0.14	0.36	8275
2026-01-29	FATE	1.19	0.14	0.05	8343
2026-01-30	FATE	1.19	0.13	0.04	8454
2026-02-02	FATE	1.225	0.13	0.27	8661
2026-02-03	FATE	1.155	0.13	0.42	8723
2026-02-05	FATE	1.055	0.13	0.23	9031
2026-02-09	FATE	1.125	0.12	0.38	9229
2026-02-10	FATE	1.09	0.12	1.00	9237
2026-02-11	FATE	1.175	0.12	999.99	9238
2026-02-12	FATE	1.2	0.12	0.01	9291
2026-02-13	FATE	1.255	0.12	0.10	9492
2026-02-17	FATE	1.34	0.12	0.01	9484
2026-02-18	FATE	1.365	0.12	0.01	9252
2026-02-19	FATE	1.39	0.13	0.00	9155
2026-02-20	FATE	1.455	0.12	0.31	9742
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	FATE	1.21	37.6	-	-1.15
2026-01-26	FATE	1.24	37.6	-	-1.15
2026-01-27	FATE	1.31	37.6	-	-1.15
2026-01-28	FATE	1.22	37.6	-	-1.15
2026-01-29	FATE	1.20	37.6	-	-1.15
2026-01-30	FATE	1.19	37.6	-	-1.15
2026-02-02	FATE	1.23	37.6	-	-1.15
2026-02-03	FATE	1.16	37.6	-	-1.15
2026-02-04	FATE	1.14	37.6	-	-1.15
2026-02-05	FATE	1.05	37.6	-	-1.15
2026-02-06	FATE	1.13	37.6	-	-1.15
2026-02-09	FATE	1.13	37.6	-	-1.15
2026-02-10	FATE	1.10	37.6	-	-1.15
2026-02-11	FATE	1.18	37.6	-	-1.15
2026-02-12	FATE	1.20	37.6	-	-1.15
2026-02-13	FATE	1.25	37.6	-	-1.15
2026-02-17	FATE	1.34	37.6	-	-1.15
2026-02-18	FATE	1.37	37.6	-	-1.15
2026-02-19	FATE	1.39	37.6	-	-1.15
2026-02-20	FATE	1.45	38.4	-	-1.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	FATE	-0.64	1.72	9.21
2026-01-26	FATE	-0.64	1.72	9.21
2026-01-27	FATE	-0.64	1.72	9.21
2026-01-28	FATE	-0.64	1.72	10.47
2026-01-29	FATE	-0.64	1.72	10.47
2026-01-30	FATE	-0.64	1.72	10.47
2026-02-02	FATE	-0.64	1.69	10.47
2026-02-03	FATE	-0.64	1.69	10.47
2026-02-04	FATE	-0.64	1.69	10.47
2026-02-05	FATE	-0.64	1.69	10.47
2026-02-06	FATE	-0.26	1.69	10.47
2026-02-09	FATE	-0.26	2.31	10.47
2026-02-10	FATE	-0.26	2.31	10.47
2026-02-11	FATE	-0.26	2.31	10.44
2026-02-12	FATE	-0.26	2.31	10.44
2026-02-13	FATE	-0.26	2.31	10.44
2026-02-17	FATE	-0.26	4.19	10.44
2026-02-18	FATE	-0.26	4.19	10.44
2026-02-19	FATE	-0.26	4.19	10.44
2026-02-20	FATE	-0.26	4.19	10.45
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.27

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.28

Insider Transactions

-0.26

Institutional Transactions

4.19

Beta

2.2

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.7

Max Drawdown 5-Year %

-99.4

Target Price

4.94

P/E

Forward P/E

PEG

P/S

23.59

P/B

0.72

P/Free Cash Flow

EPS

-1.32

Average EPS Est. Cur. Y

-1.15

EPS Next Y. (Est.)

-1.13

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-2187.11

Relative Volume

1.31

Return on Equity vs Sector %

-95.7

Return on Equity vs Industry %

-78.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

Fate Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 181

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today

news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance

stock history FATE – Fate Therapeutics, Inc. invest stock market

stock prices FATE premarket after hours

ticker FATE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: FATE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y